COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,235 Articles (22,733 medRxiv, 8,502 bioRxiv)

Most recent first Previous |  Page 1183: Articles 11821-11830  | Next

Public acceptability of non-pharmaceutical interventions to control a pandemic in the United Kingdom: a discrete choice experiment
Loria-Rebolledo, L. E., Ryan, M., Watson, V., Genie, M. G., Sakowsky, R. A., Powell, D., Paranjothy, S.
10.1101/2021.10.12.21264883 — Posted: 2021-10-14
Increased mTOR signaling, impaired autophagic flux and cell-to-cell viral transmission are hallmarks of SARS-CoV-2 infection.
Celeste Maktura, G., Luscher Dias, T., Pereira Zambalde, E., Brenha, B., R. Amorim, M., Nunes Santos, L., Buscaratti, L., Gabriel de Angeli Elston, J., Mara, C., Camargo Silva Mancini, M., Carolina Betim Pavan, I., A. Toledo-Teixeira, D., Bispo-dos-Santos, K., L. Parise, P., Primon Muraro, S., Fabiano de Souza, G., Paula Morelli, A., Guilherme Salvino da Silva, L., Maia Santos de Castro, I., Oliveira Barbosa, G., G. Ludwig, R., L. Knittel, T., D. Saccon, T., A. Mori, M., Granja, F., F. Carvalho, H., Lamberti Pinto da Silva, L., I. Nakaya, H., Luiz Proenca-Modena, J., Moreira Simabuco, F., Marques-Souza, H.
10.1101/2021.10.13.464225 — Posted: 2021-10-14
The adenosine analogue prodrug ATV006 is orally bioavailable and has potent preclinical efficacy against SARS-CoV-2 and its variants
Cao, L., Li, Y., Yang, S., Li, G., Zhou, Q., Sun, J., Xu, T., Yang, Y., Zhu, T., Huang, S., Ji, Y., Cong, F., Luo, Y., Zhu, Y., Luan, H., Zhang, H., Chen, J., Liu, X., Wang, P., Yu, Y., Xing, F., Ke, B., Zheng, H., Deng, X., Zhang, W., Li, C., Zhang, Y., Zhao, J., Zhang, X., Guo, D.
10.1101/2021.10.13.463130 — Posted: 2021-10-14
Public T-cell epitopes shared among SARS-CoV-2 variants are presented on prevalent HLA class I alleles
Meyer, S., Blaas, I., Bollineni, R. C., Delic-Sarac, M., Tran, T. T., Knetter, C., Dai, K.-Z., Stove Madssen, T., Vaage, J. T., Gustavsen, A., Yang, W., Haug Nissen-Meyer, L. S., Douvlataniotis, K., Laos, M., Nielsen, M. M., Thiede, B., Soraas, A., Lund-Johansen, F., Rustad, E. H., Olweus, J.
10.1101/2021.10.13.463911 — Posted: 2021-10-14
Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry
Park, Y.-J., De Marco, A., Starr, T. N., Liu, Z., Pinto, D., Walls, A. C., Zatta, F., Zepeda, S. K., Bowen, J. E., Sprouse, K. S., Joshi, A., Giurdanella, M., Guarino, B., Noack, J., Abdelnabi, R., Foo, S.-Y. C., Lempp, F. A., Benigni, F., Snell, G., Neyts, J., Whelan, S. P., Virgin, H. W., Bloom, J. D., Corti, D., Pizzuto, M. S., Veesler, D.
10.1101/2021.10.13.464254 — Posted: 2021-10-14
Examining the Association between the COVID-19 Pandemic and Self-Harm Death Counts in Four Canadian Provinces
Isnar, S., Oremus, M.
10.1101/2021.10.13.21264961 — Posted: 2021-10-14
COVID-19 and Mental Health: Predicted Mental Health Status is Associated with Clinical Symptoms and Pandemic-Related Psychological and Behavioral Responses
Chung, J. Y., Gibbons, A., Atlas, L., Ballard, E., Ernst, M., Japee, S., Farmer, C., Shaw, J., Pereira, F.
10.1101/2021.10.12.21264902 — Posted: 2021-10-14
Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant(B.1.617.2) of SARS-CoV-2
Pattni, K., Hungerford, D., Adams, S., Buchan, I., Cheyne, C. P., Garcia-Finana, M., Hall, I., Hughes, D. M., Overton, C., Zhang, X., Sharkey, K. J.
10.1101/2021.10.12.21264840 — Posted: 2021-10-14
Differentiation of SARS-CoV-2 naturally infected and vaccinated individuals in an inner-city emergency department
Beck, E. J., Hsieh, Y.-H., Fernandez, R. E., Dashler, G., Egbert, E. R., Truelove, S. A., Garliss, C., Wang, R., Bloch, E. M., Shrestha, R., Blankson, J. N., Cox, A. L., Manabe, Y. C., Kickler, T., Rothman, R. E., Redd, A. D., Tobian, A. A., Quinn, T. C., Laeyendecker, O.
10.1101/2021.10.13.21264968 — Posted: 2021-10-14
Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominanceof Delta variant (B.1.617.2), August-September 2021, the Netherlands
de Gier, B., Andeweg, S., Backer, J. A., Hahne, S. J. M., van den Hof, S., de Melker, H. E., Knol, M. J.
10.1101/2021.10.14.21264959 — Posted: 2021-10-14 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).